The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Abstract
A mutated cyclin-dependent kinase 4 (CDK4) was identified as a tumor-specific antigen recognized by HLA-A2. 1-restricted autologous cytolytic T lymphocytes (CTLs) in a human melanoma. The mutated CDK4 allele was present in autologous cultured melanoma cells and metastasis tissue, but not in the patient's lymphocytes. The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16 INK4a , but not of p21 or of p27 KIP1 . The same mutation was found in one additional melanoma among 28 melanomas analyzed. These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16 INK4a .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Self-citationA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
A role for sunlight in skin-cancer – UV-induced p53 mutations in squamous-cell carcinoma
Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., & Pontén, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.10124 · Cited by 1,959
Cited by
Items 101–149 of 149
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
Cloning Genes Encoding MHC Class II-Restricted Antigens: Mutated CDC27 as a Tumor Antigen
Wang, R.-F., Wang, X., Atwood, A. C., Topalian, S. L., & Rosenberg, S. A. (1999) · Science · doi:10.1126/science.284.5418.1351 · Cited by 300
Active immunization against cancer with dendritic cells: The near future
Steinman, R. M., & Dhodapkar, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1503 · Cited by 299
J�ger, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., J�ger, D., Ilsemann, C., Hagedorn, M., Oesch, F., & Knuth, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960703)67:1<54::aid-ijc11>3.0.co;2-c · Cited by 299
Human tumor antigens for cancer vaccine development
Wang, R., & Rosenberg, S. A. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01331.x · Cited by 296
Differentiation therapy of human cancer: basic science and clinical applications
Leszczyniecka, M., Roberts, T., Dent, P., Grant, S., & Fisher, P. B. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00132-2 · Cited by 292
The Molecular Balancing Act of p16INK4a in Cancer and Aging
LaPak, K. M., & Burd, C. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 291
Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., & Lotze, M. T. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118958 · Cited by 289
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., Mortarini, R., Arancia, G., Anichini, A., Fais, S., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18809.x · Cited by 289
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
Beà, S., Ribas, M., Hernández‐Rivas, J. M., Bosch, F., Pinyol, M., Hernández, L., Garcı́a, J. L., Flores, T., González, M., López‐Guillermo, A., et al. (1999) · PubMed · doi:10.1182/blood.v93.12.4365 · Cited by 284
Signaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes
Wang, R.-F., Appella, E., Kawakami, Y., Kang, X., & Rosenberg, S. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2207 · Cited by 272
Liu, Z.-J., Xiao, M., Balint, K., Smalley, K. S. M., Brafford, P., Qiu, R., Pinnix, C. C., Li, X., & Herlyn, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3589 · Cited by 271
The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity
Wang, R.-F. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01896-8 · Cited by 266
Does the Immune System Naturally Protect Against Cancer?
Corthay, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00197 · Cited by 261
The INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 261
Structural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
Topalian, S. L., Gonzales, M. I., Parkhurst, M., Li, Y. F., Southwood, S., Sette, A., Rosenberg, S. A., & Robbins, P. F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.5.1965 · Cited by 257
The Retinoblastoma Protein Pathway in Cell Cycle Control and Cancer
Bartek, J., Bartkova, J., & Lukas, J. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3776 · Cited by 254
Role of the retinoblastoma protein in the pathogenesis of human cancer.
Sellers, W. R., & Kaelin, W. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3301 · Cited by 253
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., & DeLeo, A. B. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1357 · Cited by 253
Wide spectrum of tumors in knock‐in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
Sotillo, R., Dubus, P., Martn, J., de la Cueva, E., Ortega, S., Malumbres, M., & Barbacid, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6637 · Cited by 208
Brotherton, D. H., Dhanaraj, V., Wick, S., Brizuela, L., Domaille, P. J., Volyanik, E., Xu, X., Parisini, E., Smith, B. O., Archer, S. J., et al. (1998) · Nature · doi:10.1038/26164 · Cited by 210
Self-citationTigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Parry, D., Mahony, D., Wills, K., & Lees, E. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1775 · Cited by 174
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558114 · Cited by 170
Rane, S. G., Cosenza, S. C., Mettus, R. V., & Reddy, E. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.2.644-656.2002 · Cited by 167
Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166
p16 INK4A Participates in a G 1 Arrest Checkpoint in Response to DNA Damage
Shapiro, G. I., Edwards, C. D., Ewen, M. E., & Rollins, B. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.378 · Cited by 165
Tumor suppressor p16 INK4A is necessary for survival of cervical carcinoma cell lines
McLaughlin-Drubin, M. E., Park, D., & Munger, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310432110 · Cited by 163
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
MHC Class I Antigens and Immune Surveillance in Transformed Cells
Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)56005-5 · Cited by 145
Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133
Martín, J., Hunt, S. L., Dubus, P., Sotillo, R., Néhmé-Pélluard, F., Magnuson, M. A., Parlow, A. F., Malumbres, M., Ortega, S., & Barbacid, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206506 · Cited by 122
Mettus, R. V., & Rane, S. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206888 · Cited by 97
The genetics of melanoma: recent advances
Hill, V. K., Gartner, J. J., Samuels, Y., & Goldstein, A. M. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153429 · Cited by 86
Smad3 phosphorylation by cyclin-dependent kinases
LIU, F. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.010 · Cited by 71
CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation
Lopez-Mejia, I. C., Lagarrigue, S., Giralt, A., Martinez-Carreres, L., Zanou, N., Denechaud, P.-D., Castillo-Armengol, J., Chavey, C., Orpinell, M., Delacuisine, B., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.034 · Cited by 71
Wei, W., Jobling, W. A., Chen, W., Hahn, W. C., & Sedivy, J. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.8.2859-2870.2003 · Cited by 68
Mart�n, J., Usac, E. F., Franco, C., Barbacid, M., Gomis, R., Marzo, N., Mora, C., & Fabregat, M. E. (2004) · Diabetologia · doi:10.1007/s00125-004-1372-0 · Cited by 65
Steitz, J., Britten, C. M., Wölfel, T., & Tüting, T. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0042-5 · Cited by 65
Self-citationQi, L., Rojas, J.-M., & Ostrand-Rosenberg, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5451 · Cited by 60
An update on the implications of cyclin D1 in melanomas
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., Ayén, Á., & Ramos‐García, P. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12874 · Cited by 49
Challenges targeting cancer neoantigens in 2021: a systematic literature review
Chen, I., Chen, M. Y., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1935248 · Cited by 39
Javorovic, M., Pohla, H., Frankenberger, B., Wölfel, T., & Schendel, D. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.034 · Cited by 33
Self-citationSleep Deprivation Increases Mortality in Female Mice Bearing Ehrlich Ascitic Tumor
Maragno-Correa, J. M. R., Patti, C. L., Zanin, K. A., Wuo-Silva, R., Ruiz, F. S., Zager, A., Sá-Nunes, A., Tufik, S., Andersen, M. L., & Frussa-Filho, R. (2013) · Neuroimmunomodulation · doi:10.1159/000346201 · Cited by 26
Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells
Li, J., Xu, M., Yang, Z., Li, A., & Dong, J. (2010) · Cancer Investigation · doi:10.1080/07357900903286966 · Cited by 26
Immortalization of primary marmoset skin fibroblasts by CRISPR-Cas9-mediated gene targeting
Jeong, Y.-J., Cho, J., Kwak, J., Sung, Y. H., & Kang, B.-C. (2022) · Animal Cells and Systems · doi:10.1080/19768354.2022.2151509 · Cited by 11
Metadata
- Authors
- Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D.
- Venue
- Science
- Published
- 1995-09
- Volume
- 269
- Issue
- 5228
- Pages
- 1281-1284
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2052912081
- Cited by
- 1,154
- References
- 48
- FWCI
- 25.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.